Two-thirds of financial advisors are changing their retirement investment advice for clients due to a volatile market and economic uncertainty. https://t.co/jRTTG6Ds4X ...

Company Overview - Serina Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing drug candidates for neurological diseases and other indications using its proprietary POZ Platform™ technology [7] - The company is headquartered in Huntsville, Alabama, on the campus of the HudsonAlpha Institute of Biotechnology [7] Industry Context - The biotechnology sector is currently experiencing a bear market, with approximately 25% of the 700 to 800 publicly traded US biotech companies having negative enterprise values [3] - The upcoming webinar event titled "Is the Beaten Down Biotech Sector the Smartest Bet in Today's Volatile Market?" aims to discuss investment opportunities in this challenging environment [2][3] Event Details - Serina's CEO, Steven A. Ledger, will present at the Tribe Public's Webinar on June 11, 2025, at 8:30 am Pacific / 11:30 am Eastern [2] - Participants can submit questions for the CEO before and during the event, which will be hosted by Tribe Public's Managing Member, John F. Heerdink, Jr. [6]

The market is a greedy machine with many objectives, one of which is to transfer money from impatient and short-sighted investors into the hands of the savvy and patient. In today’s uncertainty and volatility, born out of President Trump's recent trade tariff rollouts, there are new opportunities for savvy and patient investors to lock in great deals. Knowing that tariff fears will inevitably subside and that discounts can be had pretty much all over the marketplace today, investors can start to look into s ...

Group 1 - Tevogen Bio Holdings Inc. will have its CEO, Dr. Ryan Saadi, participate in BioNJ's Fifteenth Annual Bio Partnering Conference, focusing on strategies for adapting to market volatility [1][2] - The conference aims to foster strategic partnerships and drive funding within the biopharmaceutical industry, ultimately advancing medical innovation [2][3] - Dr. Saadi emphasized the importance of addressing market volatility and its impact on patient outcomes, aligning with Tevogen Bio's mission to enhance accessibility to lifesaving treatments [3] Group 2 - The conference will feature a dynamic agenda including 1:1 partnering sessions, company pitch presentations, and extensive networking opportunities designed for growth and collaboration [3] - BioNJ President and CEO Debbie Hart expressed excitement for the panel discussion, highlighting the potential for attendees to gain actionable insights [3]

Core Insights - Tevogen Bio Holdings Inc. will participate in BioNJ's Fifteenth Annual Bio Partnering Conference, focusing on strategies for adapting to market volatility [1][2] - The conference aims to foster strategic partnerships and drive funding within the biopharmaceutical industry, ultimately advancing medical innovation [2][3] Company Participation - CEO Dr. Ryan Saadi will be featured in a panel discussion titled "Paths to Liquidity: Strategies for Adapting to a Volatile Market" [1] - The panel will include notable industry figures from J.P. Morgan Private Bank, RSM US, and Cantor Fitzgerald, indicating a strong representation of financial expertise [1] Industry Context - The biotechnology industry is currently facing market volatility, which could impact patient outcomes, highlighting the importance of discussions at the conference [3] - The conference will include various activities such as 1:1 partnering sessions, company pitch presentations, and extensive networking opportunities, designed to support growth and collaboration in the industry [3]